ANI PHARMACEUTICALS INC (ANIP)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, ANI PHARMACEUTICALS INC reported revenue of $883.37M, up 43.8% from the prior year. The company was profitable, with a net margin of 8.9%. It held $1.44B in total assets against $899.65M in total liabilities.
Key ratios (FY2025)
12.6%
Operating margin
8.9%
Net margin
14.5%
Return on equity
+43.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $883.37M | $614.38M | $486.82M | $316.38M | $216.14M | $208.47M | $206.55M | $201.58M | $176.84M | $128.62M |
| Cost of Revenue | — | — | — | — | — | $87.16M | $63.15M | $73.02M | $79.03M | $48.78M |
| Operating Income | $111.09M | $584.0K | $46.97M | -$35.28M | -$39.79M | -$16.02M | $16.35M | $35.36M | $28.33M | $20.08M |
| Net Income | $78.34M | -$18.52M | $18.78M | -$47.90M | -$42.60M | -$22.55M | $6.09M | $15.49M | -$1.08M | $3.93M |
| EPS (Diluted) | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 | $-1.88 | $0.50 | $1.30 | $-0.09 | $0.34 |
| Total Assets | $1.44B | $1.28B | $904.42M | $760.09M | $771.60M | $461.19M | $456.79M | $430.60M | $412.14M | $322.86M |
| Total Liabilities | $899.65M | $855.94M | $446.82M | $421.55M | $412.86M | $265.49M | $244.00M | $233.34M | $237.38M | $153.22M |
| Shareholders' Equity | $540.72M | $403.68M | $432.75M | $313.69M | $333.89M | $195.70M | $212.79M | $197.26M | $174.76M | $169.65M |
| Cash & Equivalents | $285.58M | $144.86M | $221.12M | $48.23M | $100.30M | $7.86M | $62.33M | $43.01M | $31.14M | $27.36M |
| Operating Cash Flow | $185.22M | $64.02M | $118.96M | -$31.20M | $3.32M | $15.27M | $45.63M | $67.07M | $39.42M | $27.47M |
| Capital Expenditures | $13.84M | $16.24M | $8.87M | $8.88M | $2.56M | $6.13M | $6.63M | $5.74M | $10.37M | $4.57M |
| Shares Outstanding | 21.23M | 19.32M | 18.19M | 16.26M | 12.60M | 11.96M | 12.04M | 11.77M | 11.55M | 11.57M |